Blenkinsop A, van der Flier W M, Wolk D, Lehmann M, Howard R, Frost C, Barnes J
Institute of Clinical Trials and Methodology, University College London, London, UK.
Department of Neurology, Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Eur J Neurol. 2020 Jun;27(6):995-1002. doi: 10.1111/ene.14185. Epub 2020 Mar 29.
Memory is known to be the most common first symptom in Alzheimer's disease (AD). Assessing non-memory cognitive symptom development in AD is important for understanding disease progression and the potential identification of treatment-responsive subtypes.
Data from the National Alzheimer's Coordinating Center were examined. Logistic regression models were fitted evaluating the development of judgement, language, visuospatial and attention symptoms at first and second visits to Alzheimer's Disease Centers. Predictors were age and prior symptoms, adjusting for symptom length and sex. The models were then refitted assessing apolipoprotein E ε4 (APOE-ε4) effects.
Each decade reduction in presentation age increased the odds of language, visuospatial and attention symptom development at both visits by 8%-18% (P < 0.05, all tests), and judgement symptoms at the second visit by 13% (P < 0.05). Prior symptoms were not equally predictive of symptom development. For example, having first predominant language symptoms carried the lowest risk of developing other first-visit symptoms and having memory symptoms was a stronger predictor of developing judgement than other symptoms. The APOE-ε4 gene showed little impact on symptom development when included as a predictor.
Our findings provide support for the concept that younger-onset AD is associated with the progressive development of more non-memory symptoms beyond the first time point. Associations between symptoms were evident, which may reflect that pathology can remain isolated in a network for some time. APOE-ε4 status had little influence on cognitive symptom development which may indicate that the effect it has occurs very early in the disease course.
记忆是已知的阿尔茨海默病(AD)最常见的首发症状。评估AD中非记忆性认知症状的发展对于理解疾病进展以及潜在识别治疗反应性亚型至关重要。
对来自国家阿尔茨海默病协调中心的数据进行了检查。拟合逻辑回归模型,评估在首次和第二次就诊于阿尔茨海默病中心时判断、语言、视觉空间和注意力症状的发展情况。预测因素为年龄和既往症状,并对症状持续时间和性别进行了校正。然后重新拟合模型以评估载脂蛋白Eε4(APOE-ε4)的影响。
就诊年龄每降低一个十年,语言、视觉空间和注意力症状在两次就诊时发展的几率增加8%-18%(P<0.05,所有检验),第二次就诊时判断症状发展的几率增加13%(P<0.05)。既往症状对症状发展的预测作用并不相同。例如,最初以语言症状为主的患者出现其他首次就诊症状的风险最低,且记忆症状比其他症状更能预测判断症状的发展。当将APOE-ε4基因作为预测因素纳入时,其对症状发展的影响较小。
我们的研究结果支持以下概念,即早发型AD与首次时间点之后更多非记忆症状的渐进性发展相关。症状之间的关联很明显,这可能反映出病理状态在一段时间内可在一个网络中保持孤立。APOE-ε4状态对认知症状发展影响较小,这可能表明其作用在疾病进程中很早就已发生。